Selecting patients for treatment with immunotherapy: Our experience in a resource-deprived economy
Open Access
- 27 October 2020
- journal article
- Published by Peertechz Publications Private Limited in International Journal of Immunotherapy and Cancer Research
- Vol. 6 (1), 025-027
- https://doi.org/10.17352/2455-8591.000027
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast CarcinomasAsian Pacific Journal of Cancer Prevention, 2019
- MicroRNA (miRNA) in cancerCancer Cell International, 2015
- Survival after sorafenib: Expect the unexpectedJournal of Hepatology, 2014
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignanciesClinical Therapeutics, 2006
- Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005